Clinical and Translational Research
Copyright ©The Author(s) 2021.
World J Gastroenterol. Feb 21, 2021; 27(7): 609-623
Published online Feb 21, 2021. doi: 10.3748/wjg.v27.i7.609
Table 1 Participant demographics

Total (n = 145), mean ± SD (% of cohort)
NASH
NAFL
Total cohort (n)1458758
Sex (male)88 (60.7%)4642a
Age60.2 ± 13.160.9 ± 13.259 ± 12.9
BMI average28.8 ± 4.729.9 ± 4.427.1 ± 4.8c
Normal BMI (≥ 18.5 ≤ 22.9)21.4 ± 1.6 (n = 17)n = 6 n = 12
Overweight (≥ 23.0 ≤ 27.9)25.6 ± 1.1 (n = 43)n = 26 n = 26
Obese (≥ 27.5)32.1 ± 3.2 (n = 82)n = 55n = 20
Blood serum tests
AST (IU/L)47.8 ± 27.556.4 ± 29.834.8 ± 17.1c
ALT (IU/L)59.8 ± 49.371.3 ± 51.542.6 ± 41.4c
GGT85.9 ± 78.497.8 ± 85.869.3 ± 62.9b
Total bilirubin (mg/dL)0.86 ± 0.40.8 ± 0.30.9 ± 0.4
Platelets (× 104/μL)19.4 ± 7.319.9 ± 7.518.8 ± 7
HbA1C (%)6.5 ± 1.16.6 ± 1.06.5 ± 1.1
Fasting insulin (mU/mL)20 ± 14.220.6 ± 11.619 ± 17.4
Fasting blood glucose (mg/dL)124 ± 34.7126.1 ± 32.5120.8 ± 37.8
Albumin (g/dL)4.3 ± 0.54.3 ± 0.44.2 ± 0.5
Non-invasive test
cT1871 ± 102 (n = 143)907 ± 90 (n = 87)817 ± 96c (n = 56)
MR liver fat11.4 ± 6.1 (n = 143)13.6 ± 5.8 (n = 87)8.1 ± 5.1c (n = 56)
CAP294.3 ± 47.4 (n = 117)309.1 ± 37.1 (n = 74)268.9 ± 52.7c (n = 43)
VCTE-LSM12.8 ± 9.5 (n = 117)13 ± 8.4 (n = 74)12.5 ± 11.1 (n = 43)
MRE4.2 ± 1.7 (n = 144)4.3 ± 1.5 (n = 88)4.1 ± 1.9 (n = 56)
SE9.3 ± 2.7 (n = 84)9.6 ± 2.4 (n = 50)8.8 ± 3.1 (n = 33)
Reported pre-existing conditions
Hypertensiven = 71n = 45n = 26
Dyslipidaemicn = 111n = 72n = 39
Reported as diabeticn = 97n = 59n = 38
Table 2 Range of histology scores reported across the entire cohort
Histology scores from biopsy (n = 144)

Score
Total
NASH
NAFL
Steatosis (Brunt)013013
1743637
235305
321201
Lobular inflammation01301
1914851
235359
3430
Ballooning039039
1725516
232311
3000
Fibrosis (Kleiner)0510
1241014
2271611
3553915
4311912
NAS 0000
1505
223022
326026
425251
537352
616160
7880
8220
Table 3 Spearman's correlation coefficients for all variables

cT1, (n = 143)
MR liver fat (n = 143)
MRE (n = 144)
VCTE-LSM (n = 117)
CAP (n = 117)
2D SWE (n = 84)
Fibrosis0.24, P < 0.01-0.25, P <0.010.75, P < 0.0010.69, P < 0.0010.05, P = 0.580.72, P < 0.001
Steatosis0.29, P < 0.0010.70, P < 0.001-0.23, P < 0.01-0.09, P = 0.230.39, P < 0.001-0.07, P = 0.53
Lobular inflammation0.31, P < 0.0010.28, P < 0.0010.16, P < 0.010.15, P = 0.100.26, P < 0.010.16, P = 0.15
Ballooning0.39, P < 0.0010.29, P < 0.0010.32, P < 0.010.29, P < 0.010.33, P < 0.0010.34, P < 0.001
NAS0.58, P < 0.0010.64, P < 0.0010.06, P = 0.440.13, P = 0.130.49, P < 0.0010.16, P = 0.13
Table 4 Inter-rater variability between the three pathologists for each histology metric
Histological metric
Pathologists
Kappa weighted
Lower CI
Upper CI
ASE
P value
Overall inter-rater variability (Krippendorff’s alpha)
Steatosis1 vs 20.6090.5170.70.0467< 0.00010.584
1 vs 30.4830.3880.5790.0489< 0.0001
2 vs 30.5850.4850.6860.0513< 0.0001
Lobular inflammation1 vs 20.1180.06310.1730.0281< 0.00010.109
1 vs 30.03760.005740.06950.01630.02
2 vs 30.1790.06990.2880.05560.001
Ballooning1 vs 20.2970.2050.3890..047< 0.00010.398
1 vs 30.4590.3440.5730.0583< 0.0001
2 vs 30.270.180.360.0453< 0.0001
Fibrosis1 vs 20.7190.650.7880.0353< 0.00010.398
1 vs 30.5710.4960.6470.0386< 0.0001
2 vs 30.5970.5210.6720.0385< 0.0001
NAS1 vs 20.2790.2020.3570.0398< 0.00010.421
1 vs 30.2440.1720.3160.0366< 0.0001
2 vs 30.4340.350.5180.043< 0.0001

  • Citation: Imajo K, Tetlow L, Dennis A, Shumbayawonda E, Mouchti S, Kendall TJ, Fryer E, Yamanaka S, Honda Y, Kessoku T, Ogawa Y, Yoneda M, Saito S, Kelly C, Kelly MD, Banerjee R, Nakajima A. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. World J Gastroenterol 2021; 27(7): 609-623
  • URL: https://www.wjgnet.com/1007-9327/full/v27/i7/609.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v27.i7.609